Enliven Therapeutics, Inc.

What they do

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics using a precision medicine approach. Its lead program, ELVN-001, is a selective BCR::ABL1 kinase inhibitor for chronic myeloid leukemia (CML), currently in clinical trials. The company is also exploring strategic alternatives for ELVN-002 and has deprioritized its development. It relies on third parties for manufacturing and has no products approved for commercial sale.

Revenue drivers

• No approved products — The company has no commercial revenue; all operations are funded by equity offerings and investments.
• ELVN-001 (BCR-ABL program) — Lead product candidate in Phase 1/3-ready development for CML; primary value driver and focus of all R&D spending.
• Other research-stage programs — Early-stage opportunities aligned with small molecule approach; no clinical data or revenue yet.

Recent performance

In Q2 2026, Enliven reported a net loss of $32.5 million, compared to $25.3 million in Q2 2025. R&D expenses rose to $29.0 million from $21.5 million, and G&A expenses increased to $8.2 million from $7.1 million. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $895.2 million, with an accumulated deficit of $403.3 million. Annual net losses were $103.7 million for 2025 and $89.0 million for 2024.

Strategy

Management is concentrating resources on advancing ELVN-001, including preparations for the ENABLE-2 Phase 3 trial. They have deprioritized ELVN-002 to focus on ELVN-001's pivotal program. The company relies on third-party manufacturing and plans to continue raising capital to fund operations. Key priorities include finalizing Phase 3 design discussions with the FDA and initiating the trial in the second half of 2026.

Risks

• Clinical and regulatory risk — ELVN-001 is in early-stage development; Phase 1 results may not predict Phase 3 success, and FDA approval is uncertain.
• Single program dependence — Substantially dependent on ELVN-001; failure to advance or commercialize it would materially harm the business.
• No revenue and ongoing losses — The company has never generated product revenue and expects significant net losses and negative cash flows to continue.
• Capital needs — Future expenses will increase substantially; existing cash runway into 2030 depends on current operating plan and may require additional funding.

Outlook

Management expects to initiate the ENABLE-2 Phase 3 trial in the second half of 2026, following alignment with the FDA on key trial design components. The 80 mg QD dose was selected for Phase 3. The company anticipates an End-of-Phase 2 meeting in Q3 2026 to finalize additional trial details. Cash of $895.2 million is expected to provide runway into 2030.